EU/3/01/068

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in December 2008 on request of the Sponsor.

On 19 December 2001, orphan designation (EU/3/01/068) was granted by the European Commission to Kendle International Limited, United Kingdom, for thalidomide for the treatment of multiple myeloma.

Key facts

Active substance
Thalidomide
Disease / condition
Treatment of multiple myeloma
Date of decision
19/12/2001
Outcome
Withdrawn
Orphan decision number
EU/3/01/068

Sponsor's contact details

Kendle International Ltd
Angel House
24 Station Road
Ely, Cambs CB7 4BS
United Kingdom
Telephone: +44 13 53 66 97 89
Telefax: +44 13 53 66 84 73
E-mail: info.ely@kendle.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • International Myeloma Foundation (UK)
    Lower Ground Floor
    37 York Place
    Edinburgh
    Scotland
    EH1 3HP
    United Kingdom
    Myeloma Infoline: 0800 980 3332 (freephone for UK)
    Telephone: +44 13 15 57 33 32 (Administration)
    Telefax: +44 13 15 56 97 20
    E-mail: TheIMF@myeloma.org.uk
  • Austrian Myeloma Association
    Bürglsteinstr. 21-10
    5020 Salzburg
    Austria
  • Danish Myeloma Association
    (Dansk Myelomatose Forening)
    v/ Peter Randløv
    Klosterbakken 40
    DK-3500 Værløse
    Denmark
    Telephone: +45 44 48 41 27
    E-mail: randlov@post9.tele.dk

How useful was this page?

Add your rating